Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baker Bros. Advisors Boosts Stake In Aquinox Pharmaceuticals Inc. (AQXP) to 39.8% Before Its Jump

Let’s now discuss in more detail the extent to which the positive results from the clinical trial might influence the company’s success in the future. It’s worth mentioning that analyst Biren Amin from Jefferies has recently downgraded the rating on Aquinox to “Hold” from “Buy” and reduced the price target from $13 to $2 after the company’s flagship trial of AQX-1125 in chronic obstructive pulmonary disease patients with frequent exacerbations failed to demonstrate efficacy. Nevertheless, Aquinox has just announced consistently positive results from secondary endpoints from its Phase 2 LEADERSHIP trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC) and the stock skyrocketed on Monday. Hence, there are only a few steps remaining for AQX-1125 in BPS/IC towards its commercialization. The healthcare company intends to finalize its pivotal trial designs in consultation with the U.S. Food and Drug Administration and the European Medicines Agency so as to set a path for the potential approval. Eventually, as soon as the company’s lead candidate is approved, a new flourishing revenue stream unlocks for Aquinox.

Meanwhile, the company’s financial results are weak, which is not surprising for a clinical-stage company. As of the end of June, the company has cash and cash equivalents of $29 million, down from $41 million a quarter earlier, and it posted a net loss of $4.8 million for the second quarter, slightly narrower than a loss of $5.4 million a year earlier.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.